Vascular endothelial growth factor receptor-2 induces survival of hematopoietic progenitor cells

被引:36
作者
Larrivéé, B
Lane, DR
Pollet, I
Olive, PL
Humphries, RK
Karsan, A
机构
[1] Univ British Columbia, Dept Med, Vancouver, BC V6T 1Z4, Canada
[2] Univ British Columbia, Dept Pathol & Lab Med, Vancouver, BC V6T 1Z4, Canada
[3] British Columbia Canc Agcy, Dept Med Biophys, Vancouver, BC V5Z 1L3, Canada
[4] British Columbia Canc Agcy, Dept Pathol & Lab Med, Vancouver, BC V5Z 1L3, Canada
[5] British Columbia Canc Agcy, Terry Fox Labs, Vancouver, BC V5Z 1L3, Canada
关键词
D O I
10.1074/jbc.M212158200
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Vascular endothelial growth factor ( VEGF) and its receptors play an essential role in the formation and maintenance of the hematopoietic and vascular compartments. The VEGF receptor-2 (VEGFR-2) is expressed on a population of hematopoietic cells, although its role in hematopoiesis is still unclear. In this report, we have utilized a strategy to selectively activate VEGFR-2 and study its effects in primary bone marrow cells. We found that VEGFR-2 can maintain the hematopoietic progenitor population in mouse bone marrow cultured in the absence of exogenous cytokines. Maintenance of the hematopoietic progenitor population is due to increased cell survival with minimal effect on proliferation. Progenitor survival is mainly mediated by activation of the phosphatidylinositol 3'-kinase/Akt pathway. Although VEGFR-2 also activated Erk1/2 mitogen-activated protein kinase, it did not induce cell proliferation, and blockade of this pathway only partially decreased VEGFR-2-mediated survival of hematopoietic progenitors. Thus, the role of VEGFR-2 in hematopoiesis is likely to maintain survival of hematopoietic progenitors through the activation of antiapoptotic pathways.
引用
收藏
页码:22006 / 22013
页数:8
相关论文
共 52 条
[1]   HOXB4 overexpression mediates very rapid stem cell regeneration and competitive hematopoietic repopulation [J].
Antonchuk, J ;
Sauvageau, G ;
Humphries, RK .
EXPERIMENTAL HEMATOLOGY, 2001, 29 (09) :1125-1134
[2]  
Blau C A, 1999, Prog Exp Tumor Res, V36, P162
[3]   A proliferation switch for genetically modified cells [J].
Blau, CA ;
Peterson, KR ;
Drachman, JG ;
Spencer, DM .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1997, 94 (07) :3076-3081
[4]   The phosphoinositide 3-kinase pathway [J].
Cantley, LC .
SCIENCE, 2002, 296 (5573) :1655-1657
[5]  
Carmeliet P, 1999, CURR TOP MICROBIOL, V237, P133
[6]   Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele [J].
Carmeliet, P ;
Ferreira, V ;
Breier, G ;
Pollefeyt, S ;
Kieckens, L ;
Gertsenstein, M ;
Fahrig, M ;
Vandenhoeck, A ;
Harpal, K ;
Eberhardt, C ;
Declercq, C ;
Pawling, J ;
Moons, L ;
Collen, D ;
Risau, W ;
Nagy, A .
NATURE, 1996, 380 (6573) :435-439
[7]  
Choi K, 1998, DEVELOPMENT, V125, P725
[8]   The hemangioblast: A common progenitor of hematopoietic and endothelial cells [J].
Choi, K .
JOURNAL OF HEMATOTHERAPY & STEM CELL RESEARCH, 2002, 11 (01) :91-101
[9]   Specificity and mechanism of action of some commonly used protein kinase inhibitors [J].
Davies, SP ;
Reddy, H ;
Caivano, M ;
Cohen, P .
BIOCHEMICAL JOURNAL, 2000, 351 (351) :95-105
[10]   VEGF165 promotes survival of leukemic cells by Hsp90-mediated induction of Bcl-2 expression and apoptosis inhibition [J].
Dias, S ;
Shmelkov, SV ;
Lam, G ;
Rafii, S .
BLOOD, 2002, 99 (07) :2532-2540